Mr. Armand Balboni reports

APPILI THERAPEUTICS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Appili Therapeutics Inc. has released the results from its annual and special meeting of shareholders held earlier today.

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler and Armand Balboni.

The voting results for each director are summarized in the attached table.

In addition to the election of the directors of the company, the shareholders:

• Reappointed PricewaterhouseCoopers LLP, chartered accountants, as the independent auditor of the company for the ensuing year and authorized the directors of the company to fix its remuneration;
• Approved amendments to the company's stock option plan to, inter alia, change the plan from a fixed plan to a rolling 10-per-cent plan;
• Approved the company's equity incentive plan.

The company has filed a report of the voting results on all resolutions voted on the meeting on the company's SEDAR profile.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical anti-parasitic product for the treatment of a disfiguring disease, a broad-spectrum anti-fungal and two novel antibiotic programs. Led by a proven management team, Appili is at the epicentre of the global fight against infection.